[1]叶凌霞 洪洁.多囊卵巢综合征与肠道菌群[J].国际内分泌代谢杂志,2019,39(05):345-348.[doi:10.3760/cma.j.issn.1673-4157.2019.05.014]
 Ye Lingxia,Hong Jie.Polycystic ovary syndrome and gut microbiota[J].International Journal of Endocrinology and Metabolism,2019,39(05):345-348.[doi:10.3760/cma.j.issn.1673-4157.2019.05.014]
点击复制

多囊卵巢综合征与肠道菌群()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年05期
页码:
345-348
栏目:
综述
出版日期:
2019-09-20

文章信息/Info

Title:
Polycystic ovary syndrome and gut microbiota
作者:
叶凌霞 洪洁
上海交通大学医学院附属瑞金医院内分泌代谢病科,上海市内分泌代谢病临床医学中心,上海市内分泌代谢病研究所 200025
Author(s):
Ye Lingxia Hong Jie
Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Clinical Medical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai 200025, China
关键词:
多囊卵巢综合征 肠道菌群
Keywords:
Polycystic ovary syndrome Gut microbiota
DOI:
10.3760/cma.j.issn.1673-4157.2019.05.014
摘要:
多囊卵巢综合征(PCOS)是育龄女性最常见的内分泌疾病,其病因复杂,发病机制尚未完全明确。肠道菌群作为与人体共生的巨大微生物群落,已证实与多种代谢性疾病密切相关。目前研究发现,肠道菌群可能通过损伤肠道黏膜屏障、改变菌群组成、影响肠-脑轴等机制,与PCOS的高雄激素血症、胰岛素抵抗、肥胖、慢性炎性反应等临床表现紧密联系,对其深入研究可能为PCOS患者的临床治疗提供新思路。
Abstract:
Polycystic ovary syndrome(PCOS)is the most common endocrine disease in women of childbearing age, but its etiology is complex and the pathogenesis is not completely clear. The gut microbiota, as a large symbioticmicrobial community in human body, has been shown to be closely related to a variety of metabolic diseases. At present, many studies found that the gut microbiota may be closely related to the clinical manifestations of patients with PCOS,such as hyperandrogenism, insulin resistance, obesity, and chronic inflammation, by injuring the intestinal mucosal barrier, changing the microbial composition and the gut-brain axis. It is believed that further study may provide new ideas for clinical treatment of patients with PCOS.

参考文献/References:

[1] Lindheim L,Bashir M,Münzker J,et al.Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome(PCOS):a pilot study[J].PLoS One,2017,12(1):e0168390.DOI:10.1371/journal.pone.0168390.
[2] Torres PJ,Siakowska M,Banaszewska B,et al.Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism[J].J Clin Endocrinol Metab,2018,103(4):1502-1511.DOI:10.1210/jc.2017-02153.
[3] Insenser M,Murri M,Del Campo R,et al.Gut microbiota and the polycystic ovary syndrome: influence of sex, sex hormones, and obesity[J].J Clin Endocrinol Metab,2018,103(7):2552-2562.DOI:10.1210/jc.2017-02799.
[4] Kelley ST,Skarra DV,Rivera AJ,et al.The gut microbiome is altered in a letrozole-induced mouse model of polycystic ovary syndrome[J].PLoS One,2016,11(1):e0146509.DOI:10.1371/journal.pone.0146509.
[5] Guo Y,Qi Y,Yang X,et al.Association between polycystic ovary syndrome and gut microbiota[J].PLoS One,2016,11(4):e0153196.DOI:10.1371/journal.pone.0153196.
[6] Le Chatelier E,Nielsen T,Qin J,et al.Richness of human gut microbiome correlates with metabolic markers[J].Nature,2013,500(7464):541-546.DOI:10.1038/nature12506.
[7] Karlsson FH,Tremaroli V,Nookaew I,et al.Gut metagenome in European women with normal, impaired and diabetic glucose control[J].Nature,2013,498(7452):99-103.DOI:10.1038/nature12198.
[8] Vrieze A,Van Nood E,Holleman F,et al.Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome[J].Gastroenterology,2012,143(4):913-916.e7.DOI:10.1053/j.gastro.2012.06.031.
[9] Cotillard A,Kennedy SP,Kong LC,et al.Dietary intervention impact on gut microbial gene richness[J].Nature,2013,500(7464):585-588.DOI:10.1038/nature12480.
[10] Furet JP,Kong LC,Tap J,et al.Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers[J].Diabetes,2010,59(12):3049-3057.DOI:10.2337/db10-0253.
[11] Bäckhed F,Manchester JK,Semenkovich CF,et al.Mechanisms underlying the resistance to diet-induced obesity in germ-free mice[J].Proc Natl Acad Sci U S A,2007,104(3):979-984.DOI:10.1073/pnas.0605374104.
[12] Ridaura VK,Faith JJ,Rey FE,et al.Gut microbiota from twins discordant for obesity modulate metabolism in mice[J].Science,2013,341(6150):1241214. DOI:10.1126/science.1241214.
[13] Martínez I,Lattimer JM,Hubach KL,et al.Gut microbiome composition is linked to whole grain-induced immunological improvements[J].ISME J,2013,7(2):269-280.DOI:10.1038/ismej.2012.104.
[14] Schirmer M,Smeekens SP,Vlamakis H,et al.Linking the human gut microbiome to inflammatory cytokine production capacity[J].Cell,2016,167(4):1125-1136. DOI:10.1016/j.cell.2016.10.020.
[15] Shorakae S,Teede H,de Courten B,et al.The emerging role of chronic low-grade inflammation in the pathophysiology of polycystic ovary syndrome[J].Semin Reprod Med,2015,33(4):257-269.DOI:10.1055/s-0035-1556568.
[16] Zhang D,Zhang L,Yue F,et al.Serum zonulin is elevated in women with polycystic ovary syndrome and correlates with insulin resistance and severity of anovulation[J].Eur J Endocrinol,2015,172(1):29-36.DOI:10.1530/EJE-14-0589.
[17] Barr S,Hart K,Reeves S,et al.Habitual dietary intake, eating pattern and physical activity of women with polycystic ovary syndrome[J].Eur J Clin Nutr,2011,65(10):1126-1132.DOI:10.1038/ejcn.2011.81.
[18] Louis P,Flint HJ.Formation of propionate and butyrate by the human colonic microbiota[J].Environ Microbiol,2017,19(1):29-41.DOI:10.1111/1462-2920.13589.
[19] Davila AM,Blachier F,Gotteland M,et al.Re-print of "Intestinal luminal nitrogen metabolism: role of the gut microbiota and consequences for the host"[J].Pharmacol Res,2013,69(1):114-126.DOI:10.1016/j.phrs.2013.01.003.
[20] Chang AY,Lalia AZ,Jenkins GD,et al.Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome[J].Metabolism,2017,71:52-63.DOI:10.1016/j.metabol.2017.03.002.
[21] Pedersen HK,Gudmundsdottir V,Nielsen HB,et al.Human gut microbes impact host serum metabolome and insulin sensitivity[J].Nature,2016,535(7612):376-381.
[22] Han SI,Studer E,Gupta S,et al.Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes[J].Hepatology,2004,39(2):456-463.DOI:10.1002/hep.20043.
[23] Tomlinson E,Fu L,John L,et al.Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity[J].Endocrinology,2002,143(5):1741-1747.DOI:10.1210/endo.143.5.8850.
[24] Jia C,Xu H,Xu Y,et al.Serum metabolomics analysis of patients with polycystic ovary syndrome by mass spectrometry[J].Mol Reprod Dev,2019,86(3):292-297.DOI:10.1002/mrd.23104.
[25] Wang D,Zhu W,Li J,et al.Serum concentrations of fibroblast growth factors 19 and 21 in women with gestational diabetes mellitus: association with insulin resistance, adiponectin, and polycystic ovary syndrome history[J].PLoS One,2013,8(11):e81190.DOI:10.1371/journal.pone.0081190.
[26] Arusoglu G,Koksal G,Cinar N,et al.Basal and meal-stimulated ghrelin, PYY, CCK levels and satiety in lean women with polycystic ovary syndrome: effect of low-dose oral contraceptive[J].J Clin Endocrinol Metab,2013,98(11):4475-4482.DOI:10.1210/jc.2013-1526.
[27] Moran LJ,Noakes M,Clifton PM,et al.Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition[J].J Clin Endocrinol Metab,2004,89(7):3337-3344.DOI:10.1210/jc.2003-031583.
[28] Zwirska-Korczala K,Sodowski K,Konturek SJ,et al.Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome[J].J Physiol Pharmacol,2008,59(Suppl 2):161-178.
[29] Heshmati J,Farsi F,Yosaee S,et al.The effects of probiotics or synbiotics supplementation in women with polycystic ovarian syndrome: a systematic review and meta-analysis of randomized clinical trials[J].Probiotics Antimicrob Proteins,2018,[Epub ahead of print].DOI:10.1007/s12602-018-9493-9.
[30] Esmaeilinezhad Z,Babajafari S,Sohrabi Z,et al.Effect of synbiotic pomegranate juice on glycemic, sex hormone profile and anthropometric indices in PCOS: a randomized, triple blind, controlled trial[J].Nutr Metab Cardiovasc Dis,2019,29(2):201-208.DOI:10.1016/j.numecd.2018.07.002.

相似文献/References:

[1]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
 Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(05):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[2]黄爱洁,周莹,符金香,等.青春期多囊卵巢综合征的诊治进展[J].国际内分泌代谢杂志,2016,36(05):338.[doi:10.3760/cma.j.issn.1673-4157.2016.05.14]
 Huang Aijie,Zhou Ying,Fu Jinxiang,et al.Diagnosis and treatment of polycystic ovary syndrome in adolescence[J].International Journal of Endocrinology and Metabolism,2016,36(05):338.[doi:10.3760/cma.j.issn.1673-4157.2016.05.14]
[3]王雪姣,丁晓颖,彭永德.短链脂肪酸在2型糖尿病发病机制中的作用[J].国际内分泌代谢杂志,2017,37(04):270.
 Wang Xuejiao,Ding Xiaoying,Peng Yongde..The role of short chain fatty acids in the pathogenesis of type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2017,37(05):270.
[4]顾子良 王洪东 朱大龙 毕艳.2型糖尿病治疗方法对肠道菌群的影响[J].国际内分泌代谢杂志,2018,38(04):254.[doi:10.3760/cma.j.issn.1673-4157.2018.04.009]
 Gu Ziliang,Wang Hongdong,Zhu Dalong,et al.Effects of treatment of type 2 diabetes on gut microbiota[J].International Journal of Endocrinology and Metabolism,2018,38(05):254.[doi:10.3760/cma.j.issn.1673-4157.2018.04.009]
[5]高四书 王龙 华飞.晚期糖基化终末产物与多囊卵巢综合征的关系[J].国际内分泌代谢杂志,2018,38(04):279.[doi:10.3760/cma.j.issn.1673-4157.2018.04.015]
 Gao Sishu,Wang Long,Hua Fei.Relationship between advanced glycation end-products and polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2018,38(05):279.[doi:10.3760/cma.j.issn.1673-4157.2018.04.015]
[6]陈俊秀 杜宏.肠道菌群与口服降糖药物[J].国际内分泌代谢杂志,2018,38(05):305.[doi:10.3760/cma.j.issn.1673-4157.2018.05.005]
 Chen Junxiu*,Du Hong.Intestinal microbiota and oral hypoglycemic agents[J].International Journal of Endocrinology and Metabolism,2018,38(05):305.[doi:10.3760/cma.j.issn.1673-4157.2018.05.005]
[7]夏心怡 张洪梅.肠道菌群及其代谢产物调节糖脂代谢的机制[J].国际内分泌代谢杂志,2018,38(05):309.[doi:10.3760/cma.j.issn.1673-4157.2018.05.006]
 Xia Xinyi,Zhang Hongmei.Regulating mechanism of glycolipid metabolism by intestinal microbiota and its metabolites[J].International Journal of Endocrinology and Metabolism,2018,38(05):309.[doi:10.3760/cma.j.issn.1673-4157.2018.05.006]
[8]周晓聪 张晓黎.益生菌与妊娠糖尿病的相关性[J].国际内分泌代谢杂志,2018,38(05):313.[doi:10.3760/cma.j.issn.1673-4157.2018.05.007]
 Zhou Xiaocong,Zhang Xiaoli.Relationship between probiotics and gestational diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2018,38(05):313.[doi:10.3760/cma.j.issn.1673-4157.2018.05.007]
[9]万仕炜 郁梅 方彭华 张真稳.小檗碱改善胰岛素抵抗的相关机制[J].国际内分泌代谢杂志,2018,38(05):333.[doi:10.3760/cma.j.issn.1673-4157.2018.05.012]
 Wan Shiwei*,Yu Mei,Fang Penghua,et al.Related mechanism of berberine in improving insulin resistance[J].International Journal of Endocrinology and Metabolism,2018,38(05):333.[doi:10.3760/cma.j.issn.1673-4157.2018.05.012]
[10]张晓蕾 敖娜 都健.维生素D以肠道菌群为靶点治疗非酒精性脂肪性肝病的 研究进展[J].国际内分泌代谢杂志,2019,39(05):311.[doi:10.3760/cma.j.issn.1673-4157.2019.05.006]
 Zhang Xiaolei,Ao Na,Du Jian.Advances in the treatment of non-alcoholic fatty liver disease with vitamin D targeting intestinal flora[J].International Journal of Endocrinology and Metabolism,2019,39(05):311.[doi:10.3760/cma.j.issn.1673-4157.2019.05.006]

备注/Memo

备注/Memo:
通信作者:洪洁,Email:hongjie@medmail.com.cn
Corresponding author: Hong Jie, Email:hongjie@medmail.com.cn
基金项目:国家重点研发计划“重大慢性非传染性疾病防控研究”重点专项(2018YFC1313800); 国家自然科学基金面上项目(81870582); 上海市优秀学术带头人计划(19XD1403200)
Fund program:National Key R&D Program of China(2018YFC1313800); National Natural Science Foundation of China(81870582); Program of Shanghai Academic Research Leader(19XD1403200)
更新日期/Last Update: 2019-09-20